Preclinical studies have shown that OX-40 agonists exert potent antitumor activity in several cancer types, including melanoma and breast cancer (32, 33), highlighting the therapeutic potential of OX-40 for CTCL. Here, TNFRSF4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.